基于LSD的组合疗法和双抑制剂1:癌症治疗中的新兴工具
Liang Shen1, Bo Wang1, Shao-Peng Wang1
1Key Lab of Advanced Drug Preparation Technologies, Ministry of Education of China; State Key Laboratory of Esophageal Cancer Prevention & Treatment; Key Laboratory of Henan Province for Drug Quality and Evaluation; Institute of Drug Discovery and Development; School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou 450001, Henan, China.
氨酸特异性脱甲酶1 (LSD1) 抑制剂在癌症治疗中表现有前途,许多进入临床试验. 将LSD1抑制剂与其他药物结合使用或开发多目标抑制剂可能会增强抗癌疗效.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 氨酸特异性去甲基酶1 (LSD1) 是一种转录调节剂,在许多癌症中过度表达,破坏正常的基因表达.
- 在癌症中LSD1的作用需要制定有针对性的治疗策略.
研究的目的:
- 为癌症治疗中LSD1抑制剂提供全面的概述.
- 探索LSD1抑制剂与其他抗瘤剂的组合.
- 讨论LSD1多目标抑制剂和未来的研究方向.
主要方法:
- 对LSD1抑制剂及其临床应用发表文献的综述.
- 对现有和新兴的LSD1向疗法的分析.
- 讨论组合策略和多目标策略的讨论.
主要成果:
- 已经开发出许多不可逆和可逆的LSD1抑制剂,其中有几种在临床试验中.
- 涉及LSD1抑制剂的组合疗法显示出增强的疗效.
- 双重LSD1/基因素脱乙酶 (HDAC) 抑制剂代表了一种多目标策略.
结论:
- LSD1抑制剂是一种有前途的抗癌药物.
- 组合疗法和多目标策略具有改善癌症治疗结果的巨大潜力.
- 对LSD1向药物的进一步研究是有必要的.
更多相关视频
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
11:04An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model
Published on: January 13, 2023
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy
Inhibition of Cdk Activity
Treatment Resistant Cancers
